مباشر

FierceBiotechAmid US investment tour, J&J makes $1B stop in Florida to upgrade contact lens plant Endpoints NewsGan & Lee's Phase 3 obesity successes; J&J touts multiple myeloma data FierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatment BioWorldBiggest gainers and losers for June 8-12, 2026 FierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studies Endpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staff Clinical OMICsRewriting Cancer Care Through Epigenetics FierceBiotechTraws defers midphase flu study after negative regulatory review Endpoints NewsSix leaders working on LGBTQ+ inclusion in biopharma BioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitors BioWorldCaregen reports new GLP-1R agonists

Endpoints News ١٥ يونيو ٢٠٢٦

Lilly puts its stamp at #EHA26 with Jaypirca combo data in CLL, first clinical data from Ajax buyout

Eli Lilly made a push in blood cancer at this year’s European Hematology Association meeting in Stockholm over the weekend. The drugmaker presented data for Jay...

Eli Lilly made a push in blood cancer at this year’s European Hematology Association meeting in Stockholm over the weekend. The drugmaker presented data for Jaypirca combined with the standard of care in chronic lymphocytic ...